Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case

Friday, November 9, 2007 General News J E 4
TOKYO and RIDGEFIELD, Conn., Nov. 8 Astellas Pharma Inc.and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of BoehringerIngelheim Corporation) announced today that the two companies have reached asettlement agreement with Ranbaxy to enter into a stipulation of dismissal ofthe pending U.S. litigation with regard to U.S. Patent No. 4,703,063 forFlomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs andsymptoms of benign prostatic hyperplasia (BPH).

As a result of this settlement, the case will be dismissed withoutprejudice. The settlement of the litigation provides Ranbaxy with theopportunity to launch a generic tamsulosin hydrochloride product on March 2,2010, prior to the expiration of pediatric exclusivity if such is granted bythe FDA. Further terms of the settlement will not be disclosed.For more information, please contact: Kate O'Connor, Communications & Public Relations Boehringer Ingelheim Pharmaceuticals, Inc. Tel: 203-791-6250 Mobile: 917-446-7400 Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Ranbaxy and Astellas/Boehringer Ingelheim Enter In...
inVentiv Commercial Announces Executive Promotions